VOGELXO
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
No verified direct-reference Final ANDA or unrestricted TrueDS/DS-equivalent/full-coverage exclusivity anchor is established for this exact product. Apply the approval-year DR fallback under the review policy. VOGELXO is BX-rated in the current Orange Book. Matching AB1 testosterone-pump ANDAs cannot be assigned as therapeutically equivalent to VOGELXO; its formulation and reference identity are distinct. No direct-reference Final ANDA is established.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| 8785426 | 2034-02-11 | DP/U U-1531 | N | N | TESTOSTERONE_TRANSDERMAL_GEL | — | — | — |
| 8785426 | 2034-02-11 | DP/U U-1531 | N | N | TESTOSTERONE_TRANSDERMAL_GEL Independent composition claims require testosterone, alcohol, a specified adipate/laurate/oleyl cosolvent system, a polyol system and gel-forming polymer with content limits. | — | — | — |
| 9295675 | 2034-02-11 | DP/U U-1531 | N | N | TESTOSTERONE_TRANSDERMAL_GEL | — | — | — |
| 9295675 | 2034-02-11 | DP/U U-1531 | N | N | TESTOSTERONE_TRANSDERMAL_GEL Claim 1 requires a testosterone gel with specified alcohol, adipate/laurate/oleyl cosolvents, polyols, polymer and water. It is not a compound claim. | — | — | — |
| 9662340 | 2034-02-11 | DP/U U-1531 | N | N | TESTOSTERONE_GEL_TREATMENT | — | — | — |
| 9662340 | 2034-02-11 | DP/U U-1531 | N | N | TESTOSTERONE_GEL_TREATMENT Claim 1 treats hypogonadism using a gel with defined testosterone, alcohol, cosolvent/polyol and polymer restrictions. Coverage of the therapeutic condition does not remove formulation limits. | — | — | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| No exclusivity facts are recorded in this product snapshot. | ||||||||
2026-10-11 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE
2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| 076737 / 003 | FINAL_APPROVAL · FINAL_APPROVED | 2015-03-09 | — | ACTAVIS LABORATORIES UT INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 212984 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2024-02-09 | — | ENCUBE ETHICALS PRIVATE LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 2 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| 076737 / 003 | ACTAVIS LABORATORIES UT INC | FINAL_APPROVAL · FINAL_APPROVED | 2015-03-09 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 212984 / 002 | ENCUBE ETHICALS PRIVATE LTD | FINAL_APPROVAL · FINAL_APPROVED | 2024-02-09 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
Decision evidence (4)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2034-02-11 | FTO_TAIL | Claim 1 treats hypogonadism using a gel with defined testosterone, alcohol, cosolvent/polyol and polymer restrictions. Coverage of the therapeutic condition does not remove formulation limits. | Source |
| PATENT | 2034-02-11 | FTO_TAIL | Independent composition claims require testosterone, alcohol, a specified adipate/laurate/oleyl cosolvent system, a polyol system and gel-forming polymer with content limits. | Source |
| PATENT | 2034-02-11 | FTO_TAIL | Claim 1 requires a testosterone gel with specified alcohol, adipate/laurate/oleyl cosolvents, polyols, polymer and water. It is not a compound claim. | Source |
| REGULATORY_STATUS | 2014-06-04 | DECISION_BASIS | No verified direct-reference Final ANDA or unrestricted TrueDS/DS-equivalent/full-coverage exclusivity anchor is established for this exact product. Apply the approval-year DR fallback under the review policy. VOGELXO is BX-rated in the current Orange Book. Matching AB1 testosterone-pump ANDAs cannot be assigned as therapeutically equivalent to VOGELXO; its formulation and reference identity are distinct. No direct-reference Final ANDA is established. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.